Imidazolidine-2,4,5- and pirimidine-2,4,6-triones – New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility
作者:Vladimir Burmistrov、Christophe Morisseau、Vladimir D'yachenko、Dmitry Karlov、Gennady M. Butov、Bruce D. Hammock
DOI:10.1016/j.bmcl.2019.126908
日期:2020.2
A series of inhibitors of the soluble epoxide hydrolase (sEH) containing imidazolidine-2,4,5-trione or pirimidine-2,4,6-trione has been synthesized. Inhibition potency of the described compounds ranges from 8.4 μM to 0.4 nM. The tested compounds possess higher watersolubility than their preceding ureas. Molecular docking indicates new bond between the triones and the active site of sEH that in part
Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.
The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.
本发明提供了用于抑制可溶性环氧酰胺酶及相关疾病状况的化合物。
Compounds and methods for inhibiting Cif virulence factor
申请人:Trustees of Dartmouth College
公开号:US10322118B2
公开(公告)日:2019-06-18
The present invention provides a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
Treatment of inflammatory disorders in non-human mammals
申请人:The Regents of the University of California
公开号:US10383835B2
公开(公告)日:2019-08-20
The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.